Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia
Study Details
Study Description
Brief Summary
FLT3 overexpression in acute myeloid leukemia (AML) is often caused by mutations in this gene. These mutations cause constitutive phosphorylation of FLT3 proteins leading to increased proliferation and survival, decreased apoptosis and resistance to chemotherapeutic agents in AML cells. There are two major types of FLT3 mutations- internal tandem duplication (ITD) and point mutation at 835th amino residue. AMLs with FLT3 mutations have worse prognosis and are often resistant to conventional chemotherapy. Several small molecule compounds targeting FLT3 have been in the market or in clinical trials. Therefore, identification of these mutations at the time of diagnosis will provide a better prognostic prediction, might guide the treatment selection and follow-up strategies. In this study, the investigators will develop a sensitive molecular assay to detect FLT3 mutations for future clinical application. The investigators will collect 100 AML samples with at least 20 samples with known FLT3 mutations. The investigators will compare this assay with commonly used methods and standardize the procedure to meet the requirement of clinical pathology laboratory with reasonable cost.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with confirmed diagnosis of acute myeloid leukemia
Exclusion Criteria:
- non
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Taipei Medical University - WanFang Hospital | Taipei | Taiwan |
Sponsors and Collaborators
- Taipei Medical University WanFang Hospital
Investigators
- Principal Investigator: Hsin-Gjin Eugene Liu, Taipei Medical University WanFang Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FLT3-ITD KIT